Drug news
Supplemental NDA submitted to FDA for Fanapt (iloperidone) as maintenance treatment for schizophrenia-Vanda Pharma
The FDA has accepted for review Vanda's filing of a supplemental New Drug Application (sNDA) for Fanapt (iloperidone) seeking approval as a maintenance treatment of schizophrenia in adults. Vanda is seeking approval based on the results of the REPRIEVE clinical study, which evaluated the long-term maintenance of efficacy and safety of Fanapt. The FDA has set a user fee goal date under the Prescription Drug User Fee Act of May 27, 2016.